RESEARCH GUIDE
Understanding GS-441524 research for FIP
A careful reading of published evidence: what studies report, what they cannot prove and which questions owners should take to a veterinarian.
What early field evidence reported
A 2019 prospective field trial enrolled 31 cats with FIP. Twenty-six completed the planned 12-week course; 18 remained healthy at the publication follow-up. The study was influential but was not a blinded randomised trial, and its results should not be converted into a guarantee for an individual cat.
Follow-up evidence adds context
A later long-term follow-up of cats receiving oral GS-441524 contributed information about outcomes after treatment. Observational follow-up is valuable, but product composition, case selection, monitoring and access conditions vary between reports.
Drug exposure can vary
A 2026 therapeutic drug-monitoring report analysed 728 samples from 263 cats. Using that study’s proposed concentration range, 11% of samples were below and 12% were above the range. The finding supports measured, veterinary-led monitoring; it does not create a universal dose rule.
Who was enrolled and which FIP patterns were represented?
Was identity, concentration and formulation verified?
Which clinical and laboratory outcomes were followed?
Was there a control group, blinding and complete follow-up?
Questions before sourcing a product
- Can batch identity be matched to a current Certificate of Analysis?
- Are concentration, format, storage and handling clearly stated?
- Does a veterinarian support diagnosis and monitoring?
- Is access lawful at the destination?
- Is there a plan for non-response, adverse change or relapse?
REFERENCES